IntrinsiQ Specialty Solutions (Frisco, TX), a part of AmerisourceBergen, has announced the launch of MarketTREND, an interactive, visual tool that provides oncology manufacturers with product performance and market share analytics on a weekly basis.
The tool pulls treatment data from practices’ in-office dispensing and inventory management solutions and compiles it in an online portal, which can be segmented based on the tumor type and/or class of drug the manufacturer is seeking to analyze. Through this system, manufacturers can evaluate the drug’s uptake, market share (e.g., total treatment share vs. new patient starts), how it is performing relative to other drugs in the same category, and how it is affecting the use of those comparable drugs.
Susan Weidner, Senior Vice President of Analytics at IntrinsiQ Specialty Solutions, commented: “Manufacturers are eager to obtain this type of information, especially for products that are highly-targeted, entering crowded markets, or heavily used in the community oncology space. MarketTREND’s reports give manufacturers a significant competitive advantage by providing the valuable insights needed to make more informed decisions about their products more quickly.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
2 Commerce Drive
Cranbury, NJ 08512